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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dom-
inant genetic disorder caused by mutations in ENG, ACVRL1, or SMAD4. Around
90% of HHT patients present with a heterozygous pathogenic genetic variation.
Almost all cases of HHT have a family history. Very few cases are de novo or
mosaicism. We describe a case with mutational mosaicism that would not be
observed in the clinical routine when using Sanger sequencing or a NGS read
coverage below app. 100.
Methods: DNA was extracted from peripheral blood leukocytes, and buccal
swabs. The coding region, exon–intron boundaries, and the flanking sequences of
the genes were sequenced by NGS.
Results: The proband had clinical HHT fulfilling the Curacao criteria and genetic
testing identified a frameshift mutation in ENG. The mother of the proband, also
with clinical HHT, was found negative when analyzing DNA from blood for the
familial mutation using Sanger sequencing. Analyzing her DNA by NGS HHT
panel sequencing when extracted from both peripheral blood leukocytes, and
cheek swabs, identified the familial ENG mutation at low levels.
Conclusion: We provide evidence of ENG mutational mosaicism in an individual
presenting with clinical HHT. These findings illustrate the importance of consider-
ing mutational mosaicism.
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1 | INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT), also
known as Osler–Weber–Rendu disease, is an autosomal
dominant hereditary disorder characterized by a variety
of clinical manifestations due to the presence of multi-
ple mucocutaneous telangiectases and arteriovenous mal-
formations (AVMs) in internal organs, most commonly
lungs, liver, and cerebrum. The most frequent clinical
manifestation is spontaneous and recurrent epistaxis,
affecting more than 95% of all HHT patients. Pul-
monary arteriovenous malformations (PAVMs) are
observed in about one-third of all HHT patients (Kjeld-
sen, Oxhøj, Andersen, Green, & Vase, 2000), and can
cause cerebral abscess or stroke due to paradoxical
embolism (Kjeldsen et al., 2000; Mathis et al., 2012).
Cerebral AVMs are present in at least 10% of HHT
patients and hepatic AVMs are common, but rarely
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symptomatic (Dupuis-Girod, Bailly, & Plauchu, 2010;
Faughnan et al., 2011).
HHT is a genetically heterogeneous disorder caused by
mutations in three known genes: ENG (OMIM 131195),
ACVRL1 (OMIM 601284), and SMAD4 (OMIM 600993).
HHT is a clinical diagnosis, according to the Curacao
criteria (Shovlin et al., 2000). In approximately 85% of the
HHT patients a mutation in either ENG or ACVRL1 (Tor-
ring, Brusgaard, Ousager, Andersen, & Kjeldsen, 2013)
can be identified at mutation analysis. Only around 2% of
HHT patients have mutations in SMAD4 (Gallione et al.,
2004, 2006). In NGS analysis of these genes, usually
patients present with a pathogenic genetic variant in a
heterozygous state with an equal representation of the two
alleles.
Mosaicism is defined as the presence of two or more
cell lines with different genotypes in one individual,
developed from a singular fertilized egg. Levels of mosai-
cism across tissues and body locations can show surpris-
ing variability, even within the same embryonic lineage.
This variation likely results from interplay between muta-
tion timing, cell migration and determination during
development, and tissue-specific cell-autonomous selective
effects (Campbell, Shaw, Stankiewicz, & Lupski, 2015).
Individuals with mutational mosaicism may have none,
reduced or full disease severity. Mutational mosaicism in
HHT has been described although it is very rare. A
review of the literature (August 2017) reveals four papers
describing mosaicism in HHT, confirmed or suspected by
Sanger sequencing (Best et al., 2011; Eyries et al., 2012;
Lee et al., 2011; McDonald et al., 2011). Mutational
mosaicism confirmed by NGS, which is much more pre-
cise, has, to our knowledge, only in very few cases been
described in the HHT genes.
Here we show the presence of an ENG mutational
mosaicism that would not be observed in the clinical rou-
tine if using Sanger sequencing or a NGS read coverage
below app. 100.
2 | MATERIALS AND METHODS
Danish HHT patients are referred to the Danish HHT Cen-
ter for clinical and genetic evaluation as well as for treat-
ment for HHT manifestations, especially embolization of
PAVM. This was also the case for the patients included in
this manuscript.
2.1 | Ethical compliance
Both the proband and her mother have agreed to publica-
tion of photographs and clinical information.
2.2 | DNA analysis
The ENG gene (RefSeq: NM_001114753.1) was sequenced
with targeted NGS HHT panel using the Agilent targeted
sequence capture method followed by sequencing on the
Illumina HiSeq1500 NGS platform (Illumina Inc,San
Diego, CA). The sequencing design of the assay utilized
oligonucleotides that were designed using Agilent SureDe-
sign to capture all exons, 50- and 30-UTR, and 50 kb into
the 50- and 30- UTR, and 50 kb into the flanking regions of
the exons. A SureSelectXT Reagent kit (Agilent Technolo-
gies Denmark ApS, Glostrup, Denmark) was used and run
on a single lane using paired-end sequencing at
2 9 100 bp.
Our usual algorithm used in the HHT diagnostics labo-
ratory is NGS of an HHT panel (ENG, ACVRL1 and
SMAD4), findings are confirmed by Sanger sequencing.
3 | RESULTS
3.1 | Patients
The proband is a female patient, 38 years of age: Nose-
bleeds began at the age of three, but have never occurred
more than a couple of times a month. At the age of 10 a
left-sided pneumonectomy was performed due to severe
desaturation caused by several large pulmonary arteriove-
nous malformations. The teenage years were generally
uneventful, although some dyspnea was still present. With
age, the dyspnea got worse and the patient experienced
coughing. At time of referral to the Danish HHT Center
(age 38) clinical examination revealed a few telangiectatic
lesions, which were identified at the fingertips and the lips.
Further a small cerebral AVM in the right occipital lobe,
too small for treatment, was diagnosed.
Screening for pulmonary arteriovenous malformations
was performed and 4 pulmonary AVMs at treatable size
was diagnosed along with several small ones, too small for
treatment, in the right lung (age 38). Embolization was per-
formed at three occasions, and after the last embolization,
which were at our HHT Center, saturation increased to
98% (Figure 1a: CT before last embolization). The patient
is still in follow-up.
The mother of the proband was 76 years old when she
was referred to the HHT center. At the age of 18 thoracic
surgery with removal of a pulmonary AVM had been per-
formed. She never attended any follow-up visits. She was
generally in good health without dyspnea, but at the age of
74 she experienced a brain abscess, which was treated sur-
gically. She recovered almost fully, but some deficit such
as memory loss persisted. At the same time oxygen satura-
tion was 93% and a single large PAVM was diagnosed and
embolized (Figure 1b), which resulted in an oxygen
122 | TØRRING ET AL.
saturation increase to 99%. After embolization, contrast
echocardiography showed full occlusion of the PAVM. She
suffered from nosebleeds once or twice a week, but treat-
ment has not been necessary. She did not have anemia and
there have been no signs of cerebral AVM at cerebral CT
scan. Clinical examination, at age 76, revealed few, but
typical telangiectatic lesions (Figure 1c).
Both HHT patients fulfill the Curacao criteria (4 of 4
clinical criteria).
The other family members: The sister of the proband
had no symptoms of HHT and did not carry the ENG
mutation. The parents and siblings of the probands’ mother
had no history of HHT-related symptoms.
3.2 | Molecular analysis
The proband was submitted to the HHT Center in Odense.
She fulfilled the Curacao criteria and genetic germline test-
ing on a blood sample, was performed. A heterozygous
genetic variant, c.704dupC; p.Val236Glyfs*98, was identi-
fied in the ENG gene (read count 182/333 (55%)) and con-
firmed by Sanger sequencing. No other mutation was
identified in our NGS HHT panel encompassing the genes
ENG, ACVRL1, and SMAD4. The variant c.704dupC was
not previously described in the HHT Mutations Database
(http://arup.utah.edu/database/ENG/ENG_display.php) or
HGMD (Human Gene Mutation Database). However, as it
is a truncating frameshift mutation, it was believed to be
pathogenic.
Her mother, also presenting with clinical HHT, was
found negative when analyzing for the familial mutation
using Sanger sequencing. Suspecting mosaicism, we ana-
lyzed her DNA, by NGS ENG sequencing, extracted from
both peripheral blood leukocytes, and cheek swabs. In the
blood c.704dupC was identified in 7 of 364 reads, provid-
ing evidence for mutational mosaicism with the percentage
of the variant allele at 2%. In DNA from cheek swabs
c.704dupC was identified in 257 of 2,285 reads represent-
ing mutational mosaicism of 11% (Figure 2 and Table 1).
Sanger sequencing of both tissues showed normal wildtype
and did not reveal mosaicism.
The family history was consistent with the mutation
being de novo in the mother.
4 | DISCUSSION
We here present NGS sequencing data showing mosaicism
for a pathogenic genetic variation in an individual present-
ing with symptoms of HHT. The daughter in this case had
very severe affection of her lungs. The mother also had
clear symptoms of HHT, but less severe than the index
patient. She had less severe PAVM of the lungs, though
she was unfortunate to have a cerebral abscess due to her
PAVM. Both patients fulfilled the Curacao criteria (both
had 4 of 4 clinical criteria), which, for the mother, was a
bit surprising noting the low levels of mutational mosai-
cism. This case illustrates the difficulty of counseling
mosaic individuals as the severity of symptoms cannot be
predicted from the level of mosaicism, especially as we
cannot evaluate all tissues. As the daughter inherited the
mutation the mosaicism was also present in the mother’s
germinal tissue, and, thus, we must presume that the muta-
tion occurred rather early on in the embryogenesis of the
mother. Furthermore, the level of mosaicism in the germi-
nal tissue cannot be predicted from the level of mosaicism
in blood or other tissues, which makes it difficult to assess
the risk of transmitting the mutant allele to offspring.
This finding illustrates the importance of considering
investigation for mosaicism in HHT cases, with parents that
have no sign of HHT, and who is found negative for
pathogenic genetic variants in either of the candidate genes.
The low levels of mosaicism found in the presented case
could not be detected by Sanger sequencing in the two dif-
ferent tissues. In our analysis NGS sequencing allowed
convincing detection of mutational mosaicism at the 2%
level. The mosaicism was identified after the familial vari-
ant had already been identified in the daughter, which
enhanced the probability of detection.
Even though mosaicism and de novo mutations are rare
in HHT, this study exemplifies the importance of consider-
ing mosaicism, also in patients or families with HHT.
a b c
FIGURE 1 (a) CT scan of the lung of
the proband. Two residual pulmonary
AVMs (arrows), and only one right lung
(left-sided pneumonectomy due to severe
pulmonary AVM at age 10). (b) Pulmonary
angiography of the mother, with one large
PAVM just prior to embolization. (c) The
face of the mother at age 76, with few but
typical telangiectatic lesions
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(b)
FIGURE 2 (a) Sanger sequence. Lower two rows forward and reverse sequence from the proband. Upper two lanes sequence of DNA
extracted from maternal blood. (b) NGS panel. Lower row sequence from the proband. Upper two lanes sequence of DNA extracted from
maternal blood (top) and cheek swab (middle)
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TABLE 1 Presentation of allelic read counts of blood sample




Blood Blood Cheek swab
Variant 182 7 257
Reference (wildtype) 151 357 2,028
Mosaic percentage 55% 2% 11%
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